These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1088 related articles for article (PubMed ID: 32461344)

  • 1. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
    Wang S; Li Y; Xu C; Dong J; Wei J
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
    Kim JE; Patel MA; Mangraviti A; Kim ES; Theodros D; Velarde E; Liu A; Sankey EW; Tam A; Xu H; Mathios D; Jackson CM; Harris-Bookman S; Garzon-Muvdi T; Sheu M; Martin AM; Tyler BM; Tran PT; Ye X; Olivi A; Taube JM; Burger PC; Drake CG; Brem H; Pardoll DM; Lim M
    Clin Cancer Res; 2017 Jan; 23(1):124-136. PubMed ID: 27358487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models.
    Chen CY; Wang PY; Hutzen B; Sprague L; Swain HM; Love JK; Stanek JR; Boon L; Conner J; Cripe TP
    Sci Rep; 2017 May; 7(1):2396. PubMed ID: 28539588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
    Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
    Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
    J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.